Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8828929
SERIAL NO

13131560

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NOF CORPORATIONSHIBUYA-KU TOKYO 150-6019
SAITAMA MEDICAL UNIVERSITY38 MOROHONGO MOROYAMA-MACHI IRUMA-GUN SAITAMA 350-0495
JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES1-23-1 TOYAMA SHINJUKU-KU TOKYO 1628640

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Matsui, Masanori Saitama, JP 9 69
Oda, Hiroshi Kawasaki, JP 81 702
Uchida, Tetsuya Tokyo, JP 59 493

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 9, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00